Amgen Announces Results From Large Real-World Study Showing Treatment With Repatha Reduced Risk Of Fatal Or Nonfatal Heart Attacks By 20% Compared With Ezetimibe In People With ASCVD And Prior Statin Use
Benzinga Newsdesk 1 day ago
News
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart DiseaseResults Provide Important New
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe
Study Examined More Than Half a Million Adults Living with Heart Disease
Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients
THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease (ASCVD) and prior statin use. The study followed more than 544,000 adults for up to four years. The findings were published in The American Journal of Preventive Cardiology.